

Evidence dossier - Longview Partners (Guernsey)

GetCoattail manager profile: <https://getcoattail.com/manager/longview-partners-guernsey> | CIK 0001426092 | Rank #77 of 149 tracked managers by reported 13F value.

Background: Founded: 2001 | HQ: St. Peter Port, Guernsey | Style: Specialist global equity portfolios for institutional clients | Key person: Marina Lund

Background source: https://storage.googleapis.com/advisorfinder/brochures/143875/20251210_071834.pdf

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-13 Reported total value: \$6.2B Positions: 23 Top-10 concentration: 50.1% of reported value.

Ticker	Company	Weight	Reported value
WST	West Pharmaceutical Svsc Inc	6.03%	\$371M
UNH	Unitedhealth Group Inc	5.69%	\$350M
TSM	Taiwan Semiconductor Manufac	5.48%	\$337M
TXN	Texas Instrs Inc	5.23%	\$322M
GOOGL	Alphabet Inc	4.80%	\$296M
IQV	Iqvia Hldgs Inc	4.71%	\$290M
AXP	American Express Co	4.67%	\$287M
COO	Cooper Cos Inc	4.59%	\$283M
V	Visa Inc	4.56%	\$281M
PGR	Progressive Corp	4.33%	\$266M

2. Hypothetical 13F-clone results

Window: 2016-11-07 to 2026-10-02 (40 filings). Cumulative: +203.8% CAGR: +11.88% SPY same window: cumulative +322.8%, CAGR +15.68%. Trailing CAGR - 10Y: n/a, 5Y: +6.23%, 3Y: +9.62%, 1Y: -3.06%. Max drawdown (month-end, approximate): -27.9%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2016Q3	0001085146-16-004647	2016-11-07	25
2016Q4	0001085146-17-000459	2017-02-10	27
2017Q1	0001085146-17-001127	2017-05-08	27
2017Q2	0001085146-17-001570	2017-07-26	28
2017Q3	0001085146-17-002146	2017-10-30	25
2017Q4	0001085146-18-000349	2018-02-06	22
2018Q1	0001085146-18-001079	2018-04-16	25

2018Q2	0001085146-18-001797	2018-08-01	25
2018Q3	0001085146-18-002355	2018-10-19	26
2018Q4	0001085146-19-000686	2019-02-13	27
2019Q1	0001085146-19-001572	2019-05-15	25
2019Q2	0001085146-19-002251	2019-08-13	22
2019Q3	0001085146-19-002912	2019-11-13	23
2019Q4	0001085146-20-000679	2020-02-13	24
2020Q1	0001085146-20-001515	2020-05-14	25
2020Q2	0001085146-20-002219	2020-08-14	26
2020Q3	0001085146-20-002938	2020-11-13	24
2020Q4	0001085146-21-000828	2021-02-16	25
2021Q1	0001085146-21-001700	2021-05-14	26
2021Q2	0001085146-21-002489	2021-08-13	25
2021Q3	0001085146-21-003219	2021-11-12	24
2021Q4	0001085146-22-000866	2022-02-11	25
2022Q1	0001085146-22-002083	2022-05-13	26
2022Q2	0001085146-22-003025	2022-08-12	25
2022Q3	0001085146-22-004122	2022-11-14	27
2022Q4	0001085146-23-001142	2023-02-13	26
2023Q1	0001085146-23-002314	2023-05-12	25
2023Q2	0001085146-23-003308	2023-08-11	26
2023Q3	0001085146-23-004306	2023-11-13	25
2023Q4	0001085146-24-001214	2024-02-13	25
2024Q1	0001085146-24-002467	2024-05-14	24
2024Q2	0001085146-24-003806	2024-08-13	24
2024Q3	0001085146-24-005651	2024-11-13	24
2024Q4	0001085146-25-001334	2025-02-13	24
2025Q1	0001085146-25-003163	2025-05-14	25
2025Q2	0001085146-25-005026	2025-08-13	24
2025Q3	0001426092-25-000002	2025-11-13	23
2025Q4	0001426092-26-000001	2026-02-17	23
2026Q1	0001426092-26-000002	2026-05-15	25
2026Q2	0001426092-26-000003	2026-08-13	23

4. Coverage and adjustments

Price coverage at the latest filing: 95.9% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.